What’s Next to Invest in Healthtech

Blumorpho fosters co-creation and investment for health innovation offering new and impactful value propositions.

Accelerating Health Innovation Through Collaboration

Since 2018, Blumorpho has generated more than €1 billion investment in promising companies, including HealthTech, and has developed close collaboration with health decision makers and governments. At Blumorpho, we identify cutting-edge solutions, mobilize key stakeholders, and accelerate collaborations funding within an international ecosystem. Together with our partners, we enable the emergence, adoption, and scaling of transformative health innovations.

AI, TechBio and HealthTech

These topics are at the core of health challenges today whether it concerns the scarcity of workforces, society demographic and lifestyle evolution as well as socio economics and sovereignty challenges.
AI offers opportunity to disrupt health’s trapped value by improving R&D, patient monitoring, and creating new value opportunities in new health frontiers. During our previous INPHO Venture Summit, investors in our network expressed strong interest in solutions that offer real economic value while addressing this opportunity. AI, Pharmatech and TechBio are seen as essential sectors for driving progress and creating impactful solutions with attractive economic value.

Our 2025 Action Focus

Days

Hours

Minutes

The Monaco Smart & Sustainable is live now!

New frontiers in HealthTech

AI is reshaping healthcare by accelerating research, refining predictive analytics, and enabling personalized treatments. Its economic and social potential is drawing strong interestfrom investors. Meanwhile, neuroscience is driving a medical revolution, with innovations in Brain Health and neurodegenerative disease treatments offering new hope for conditions like Alzheimer’s and Parkinson’s. Despite the brain’s many mysteries, emerging technologies are unlocking new possibilities for diagnosis, treatment, and prevention through a holistic approach. Our focus is to push new frontiers by advancing research in neuroscience, AI-driven diagnostics, and next-generation medical solutions.

Emerging Markets Leapfrogging opportunity

Health sovereignty is a key priority for emerging markets, where countries are leveraging local expertise and investing in innovation to combat infectious diseases. Blumorpho advocates for a holistic approach to health sovereignty in emerging markets by integrating local expertise, collaborating with governments, and fostering innovation. As developing countries strengthen their capabilities to address infectious diseases and climate-related health risks, Blumorpho works to build sustainable health systems through international partnerships and cutting-edge solutions.

Securing Healthcare Sovereignty

Ensuring health sovereignty has become a strategic priority for governments, particularly after global crises exposed supply chain and production vulnerabilities. To address these challenges, efforts must focus on developing localized health ecosystems to reduce dependency, boosting local manufacturing of medical supplies and vaccines to lower costs and enhance resilience, and promoting new economic models. Blumorpho actively supports this transformation by fostering co-creation, public-private partnerships, and innovative funding mechanisms to drive sustainable and autonomous health systems, with health sovereignty initiatives expected to attract over $10 billion annually by 2030*.

Our Process: Based on a 3 Step Approach

Blumorpho creates optimal conditions for financial and strategic collaborations by working closely with innovators. Through a mix of digital interactions and in-person meetings, we guide participants from initial discussions to concrete partnerships. Our value lies in facilitating access to key stakeholders, ensuring strong connections that drive impactful collaborations.

1. Aligning Opportunities: This phase brings together key stakeholders (governments, institutions, corporates, investors) addressing critical health needs, enabling them to express their interests and expectations. By fostering a shared understanding of priorities and identifying bankable challenges, it facilitates a critical assessment of opportunities and limitations of innovative solutions, paving the way for potential co-creation and collaboration processes.

2. Innovation Challenge: This phase focuses on identifying and selecting the most promising solutions to address key bankable challenges. Through an innovation call, companies submit transformative solutions, which are evaluated through discussions with industry stakeholders and investors. Our government partners are committed to implementing innovative solutions that address specific needs with the potential for broader regional deployment. For early 2025, one of our focus is on Malaria, covering prevention, detection, care, and health system organization.

3. Result Presentation: This phase focuses on finalizing collaborations through face-to-face meetings and contractual discussions. Selected companies will be showcased to private investors, governments, and corporate representatives during the What’s Next to Invest in HealthTech editions, highlighting success stories and driving their growth.

Expected outcomes

Strategic collaborations between innovative companies and health decision-makers to generate economic value while addressing specific health challenges with global scalability potential.

Targeted investments in high-potential companies to support their growth and impact.

Strengthened ecosystems and value chains in promising health sectors, fostering innovation and sustainability.

Who join us ?

Governments and public institutions position their regions as global leaders in health innovation while attracting investment and talent to drive strategic healthcare priorities.
Investors and venture capitalists gain access to high-return opportunities in HealthTech and TechBio while collaborating with public authorities and private sector leaders.
Corporates and industry leaders unlock market access through strategic alliances and align their innovation efforts with corporate social responsibility goals.
Startups and innovators benefit from funding and strategic partnerships to scale their solutions.
Philanthropies and global health organizations drive impactful initiatives for sustainable healthcare.

Why are they joining us ?

Strategic collaborations between innovative companies and health decision-makers to generate economic value while addressing specific health challenges with global scalability potential
Targeted investments in high-potential companies to support their growth and impact.
Strengthened ecosystems and value chains in promising health sectors, fostering innovation and sustainability..